JP2024532503A - Ｇｌｐ－１／ｇｉｐデュアルターゲット型ポリペプチド及び融合タンパク質並びにこれらの適用 - Google Patents

Ｇｌｐ－１／ｇｉｐデュアルターゲット型ポリペプチド及び融合タンパク質並びにこれらの適用 Download PDF

Info

Publication number
JP2024532503A
JP2024532503A JP2024514046A JP2024514046A JP2024532503A JP 2024532503 A JP2024532503 A JP 2024532503A JP 2024514046 A JP2024514046 A JP 2024514046A JP 2024514046 A JP2024514046 A JP 2024514046A JP 2024532503 A JP2024532503 A JP 2024532503A
Authority
JP
Japan
Prior art keywords
glp
seq
gip
dual target
target polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024514046A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024532503A5 (https=
Inventor
▲鵬▼ ▲蒋▼
琳 肖
林俊 周
▲麗▼▲メイ▼ 黄
▲敏▼ ▲楊▼
燕 ▲蒋▼
▲寧▼▲遠▼ ▲孫▼
▲劍▼▲銘▼ 毛
勇 李
利佳 李
林峰 郭
静 李
文佳 李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunshine Lake Pharma Co Ltd
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Publication of JP2024532503A publication Critical patent/JP2024532503A/ja
Publication of JP2024532503A5 publication Critical patent/JP2024532503A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2235—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2024514046A 2021-09-02 2022-09-01 Ｇｌｐ－１／ｇｉｐデュアルターゲット型ポリペプチド及び融合タンパク質並びにこれらの適用 Pending JP2024532503A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111026970.5 2021-09-02
CN202111026970 2021-09-02
PCT/CN2022/116513 WO2023030444A1 (zh) 2021-09-02 2022-09-01 Glp-1/gip双靶多肽、融合蛋白及其应用

Publications (2)

Publication Number Publication Date
JP2024532503A true JP2024532503A (ja) 2024-09-05
JP2024532503A5 JP2024532503A5 (https=) 2025-08-14

Family

ID=85411955

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024514046A Pending JP2024532503A (ja) 2021-09-02 2022-09-01 Ｇｌｐ－１／ｇｉｐデュアルターゲット型ポリペプチド及び融合タンパク質並びにこれらの適用

Country Status (5)

Country Link
US (1) US20250223331A1 (https=)
EP (1) EP4410827A4 (https=)
JP (1) JP2024532503A (https=)
CN (1) CN115850437A (https=)
WO (1) WO2023030444A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114617956B (zh) * 2020-12-10 2023-10-03 江苏中新医药有限公司 一种高效降糖的蛋白质药物
US12281149B2 (en) 2021-05-13 2025-04-22 Carmot Therapeutics, Inc. Modulators of G-protein coupled receptors
WO2025049610A1 (en) * 2023-08-28 2025-03-06 Shattuck Labs, Inc. Multi-action peptides
US20250270274A1 (en) * 2024-02-26 2025-08-28 Serpentide Inc. Super long-lasting glp1 or glp1/gip analogue drug for type-2 diabetes and obesity
CN120829494A (zh) * 2024-04-18 2025-10-24 苏州星曜坤泽生物制药有限公司 一种glp-1gip类似物、fgf21蛋白、三功能蛋白及其应用
WO2026046352A1 (zh) * 2024-08-30 2026-03-05 石药集团巨石生物制药有限公司 一种gip/glp-1受体共激动剂及其应用
CN118955739B (zh) * 2024-10-17 2025-02-18 华南理工大学 一种双靶点受体激动剂融合蛋白及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102105159B (zh) * 2008-06-17 2015-07-08 印第安纳大学研究及科技有限公司 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症
US20130090285A1 (en) * 2011-06-27 2013-04-11 Phasebio Pharmaceuticals, Inc. Methods of treatment with glp-1 receptor agonists
IN2014MN02304A (https=) * 2012-05-03 2015-08-07 Zealand Pharma As
HK1209034A1 (en) * 2012-06-21 2016-03-24 Indiana University Research And Technology Corporation Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function
WO2015067715A2 (en) * 2013-11-06 2015-05-14 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
WO2016131893A1 (en) * 2015-02-18 2016-08-25 Medimmune Limited Incretin fusion polypeptides
WO2021083306A1 (zh) * 2019-10-31 2021-05-06 东莞市东阳光生物药研发有限公司 Glp-1/gcg双受体激动剂多肽
CN111111264A (zh) * 2019-12-31 2020-05-08 杭州九源基因工程有限公司 制备多肽步骤中色谱固定相的再生方法

Also Published As

Publication number Publication date
US20250223331A1 (en) 2025-07-10
CN115850437A (zh) 2023-03-28
EP4410827A4 (en) 2026-04-29
WO2023030444A1 (zh) 2023-03-09
EP4410827A1 (en) 2024-08-07

Similar Documents

Publication Publication Date Title
JP2024532503A (ja) Ｇｌｐ－１／ｇｉｐデュアルターゲット型ポリペプチド及び融合タンパク質並びにこれらの適用
CN113038964B (zh) 超长效胰岛素-fc融合蛋白及使用方法
JP7268202B2 (ja) 代謝性疾患を治療するための融合タンパク質
CN115304666B (zh) 一种治疗代谢疾病的胰高血糖素类似物
CN114591415B (zh) Glp-1/gcg双受体激动剂多肽及其融合蛋白
EP2581389A1 (en) Fusion protein of exendin-4 and its analog, preparation method and use thereof
JP5855239B2 (ja) ラクトフェリン融合タンパク質及びその製造方法
CN113150172B (zh) Glp-1r/gipr双靶点激动剂融合蛋白及其制备方法与应用
CN102516393B (zh) 胰岛素模拟肽融合蛋白和突变体及其应用
WO2024152419A1 (zh) 具有多重活性的融合蛋白及其应用
CN102558362A (zh) 一种用于治疗糖尿病的融合蛋白及其制备方法
CN106397607A (zh) 重组人成纤维细胞生长因子21融合蛋白及其在制备治疗代谢疾病药物中的应用
US10017555B2 (en) Long-acting blood sugar decreasing fusion protein
EP3257523A1 (en) Use of polypeptide complex as polypeptide or protein drug carrier, method, and fusion protein complex thereof
JP2024507321A (ja) ヒトｇｌｐ－１ポリペプチド変異体及びその応用
CN118344462B (zh) 一种用于肺部给药的索马鲁肽突变体、融合蛋白及相关产品
CN106008717B (zh) 一种长效重组glp-1融合蛋白及其制备方法和用途
WO2021083306A1 (zh) Glp-1/gcg双受体激动剂多肽
EP4545571A1 (en) Fusion protein having triple activity and use thereof
CN106146667B (zh) 一种Exendin-4融合蛋白及其制备方法与用途
CN118620086B (zh) 一种治疗糖尿病的融合蛋白及其应用
CN112574286A (zh) 多肽及其应用
CN114617956A (zh) 一种高效降糖的蛋白质药物
CA3286593A1 (en) Fusion protein having triple activity and use thereof
CN1920021B (zh) 胰岛素样生长因子结合蛋白-6介导的有活性胰岛素样生长因子-ⅱ的制备方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250730

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250730